ZBIO Historical PE Ratio Notes

— Zenas BioPharma (NASDAQ: ZBIO) is a clinical-stage biopharmaceutical company focused primarily on developing innovative immunology-based therapies to treat autoimmune and rare diseases. The company leverages deep expertise in autoimmune biology & the design of monoclonal antibodies to advance its pipeline, which includes promising assets like obexelimab and other product candidates targeting unmet medical needs. When reviewing ZBIO’s historical price-to-earnings (PE) ratio, it’s vital to recognize that as an R&D-driven firm, much of Zenas’ capital is invested in clinical trials rather than generating current profits. This often means earnings are either negative or minimal, leading to a high or undefined PE ratio during development phases. As you review charts & tables, keep in mind that changes in ZBIO’s PE ratio often reflect critical milestones in clinical development, investor sentiment on future growth, and market reactions to regulatory or partnership announcements rather than consistent profit growth. Thus, the historical PE ratio for Zenas BioPharma may be less about past earnings performance and more an indicator of the market’s expectations about its future therapeutic success and commercial prospects.

On this page we presented the Zenas BioPharma Historical PE Ratio information for Zenas BioPharma' stock. The average ZBIO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 0.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ZBIO historical PE based on this TTM earnings result method is 2.0. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ZBIO historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for ZBIO had been 18.34, and the most recent quarterly earnings result, annualized, was 67.76. Meanwhile, the most recent TTM earnings summed to 14.47. From these numbers, we calculate the recent ZBIO PE on 5/15/2026 based on annualized quarterly EPS was 0.3. Based on ZBIO's history, that recent PE is elevated relative to the historical average, with the recent PE 200.0% higher than the historical average PE across our data set for Zenas BioPharma. Looking at the recent ZBIO PE on 5/15/2026 based on TTM EPS, we calculate the ratio at 1.3. Based on ZBIO's history, that recent PE is low relative to the historical average, with the recent PE 35.0% lower than the average PE across our Zenas BioPharma data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on ZBIO or any other given stock, valuation analysis for ZBIO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Zenas BioPharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ZBIO. Thanks for visiting, and the next time you need to research ZBIO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.